MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41394-025-00712-2

Медицинская библиотека · Spinal cord series and cases · 2025

The effects of nabiximols (Sativex®) on spasticity and non-motor symptoms in chronic spinal cord injury (SCI): a longitudinal prospective study.

Martins Braga Fernando, Albu Sergiu, Mariño Fernández Cecilia, Martínez Santana Virginia, Benito-Penalva Jesús, Vidal Samsó Joan

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

STUDY

DESIGN

Observational, longitudinal, prospective study.

OBJECTIVES

This study aimed to evaluate the effects of Nabiximols (Sativex®) on spasticity in chronic spinal cord injury (SCI) individuals refractory to conventional therapy. Secondary objectives included assessing its impact on functional independence, neuropathic pain, sleep quality, and depression.

SETTING

Institute Guttmann, a neurorehabilitation hospital in Badalona, Catalonia (Spain).

METHODS

Adult participants ( >18 years) with chronic SCI ( >6 months) and moderate to severe spasticity refractory to conventional treatments were recruited. All participants underwent baseline assessments and were followed up at one and two months after initiating treatment with nabiximols oromucosal spray, with individualised dose adjustments on a weekly basis. Assessed variables included spasticity, functional independence, neuropathic pain, sleep quality, depression, quality of life, and Patient Global Impression of Improvement (PGI-I).

RESULTS

Statistically significant improvements in spasticity were observed after one month (VAS decrease of 30%, p < 0.001; MAS decrease of 60%, p = 0.001) and two months (VAS decrease of 30%, p < 0.001; MAS decrease of 52%, p = 0.011) of treatment. A positive PGI-I was reported in 67% of participants. However, no significant changes were noted in spasms frequency, functional independence, neuropathic pain, or sleep quality. No significant differences in spasticity change or non-motor symptoms were found between participants with complete and incomplete SCI.

CONCLUSIONS

Nabiximols may effectively reduce spasticity in individuals with SCI resistant to conventional therapies. Given the significant impact of spasticity associated with SCI, it could be considered a viable add-on therapy for this population.

TRIAL REGISTRY: This clinical trial is registered in the EudraCT database under the identifier 2022-001777-31.

SPONSORSHIP: Almirall, S.A., Barcelona, Catalonia (Spain).

Для цитирования: Martins Braga Fernando, Albu Sergiu, Mariño Fernández Cecilia, Martínez Santana Virginia, Benito-Penalva Jesús, Vidal Samsó Joan. The effects of nabiximols (Sativex®) on spasticity and non-motor symptoms in chronic spinal cord injury (SCI): a longitudinal prospective study.. Spinal cord series and cases. 2025. DOI: 10.1038/s41394-025-00712-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.